摘要
Telisotuzumab Vedotin是靶向作用于c-Met蛋白的抗体药物偶联物。2025年5月14日,美国食品药品监督管理局通过加速评审,批准Telisotuzumab Vedotin用于治疗既往接受过全身治疗的局部晚期或转移性非鳞状非小细胞肺癌且c-Met蛋白高表达的成年患者。Telisotuzumab Vedotin是首个针对c-Met蛋白的抗体药物偶联物。本文主要介绍其作用机制、药动学、临床研究及安全性。
Telisotuzumab Vedotin is an antibody-drug conjugate targeting c-Met protein.Telisotuzumab Vedotin was approved for adult patients with locally advanced or metastatic,non-squamous non-small cell lung cancer with high c-Met protein expression by the U.S.Food and Drug Administration on May 14,2025.Telisotuzumab Vedotin is the first c-Met-targeted antibody-drug conjugate approved for clinical use.The mechanism,pharmacokinetics,clinical research and safety of Telisotuzumab Vedotin were reviewed in this article.
作者
黄佩文
王旭东
HUANG Peiwen;WANG Xudong(Department of Pharmacy,The Third Affiliated Hospital of Anhui Medical University/Hefei First People's Hospital,Hefei 230061,Anhui,China)
出处
《山东大学学报(医学版)》
2026年第3期124-130,共7页
Journal of Shandong University(Health Sciences)
